The latest research study “Immunotherapy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” by IMARC Group, finds that the global immunotherapy drugs market size reached US$ 195.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 327.8 Billion by 2028, exhibiting a growth rate (CAGR) of 8.9% during 2023-2028.
Immunotherapy drugs represent specialized medications that are used for treating melanoma, lymphoma, sarcoma, and lung, bladder, kidney, and breast cancer. They usually target specific cells of the immune system and boost energy levels. In line with this, immunotherapy drugs stimulate the natural defenses of the body and help in fighting against allergies and infections caused by viruses and bacteria. They also assist in preventing the growth of cancer cells by triggering an immunological response that generates antibodies. Furthermore, immunotherapy drugs are effective in minimizing the complications of tumors and other chronic disorders. Consequently, they are gaining extensive traction across the globe.
Immunotherapy Drugs Market Trends and Drivers:
The expanding geriatric population and the elevating prevalence of tumor and target diseases are primarily driving the immunotherapy drugs market. Additionally, the rising occurrence of numerous genetic and lifestyle disorders and the increasing awareness among healthcare professionals and individuals towards the benefits of early diagnosis and treatment of cancer are further catalyzing the market growth. Besides this, the escalating demand for monoclonal antibodies and biosimilar drugs and the growing number of hospitals, pharmacies, and research laboratories are acting as significant growth-inducing factors. Moreover, key market players are focusing on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge, which is also positively influencing the global market. Apart from this, extensive investments in R&D activities by leading pharmaceutical and biotechnology companies to enhance the formulation of these medications are expected to fuel the immunotherapy drugs market over the forecasted period.
Immunotherapy Drugs Market Report Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- GSK plc, Merck & Co. Inc.
- Pfizer Inc. and Sanofi S.A.
The report has been segmented the market into following categories:
Breakup by Type:
- Monoclonal Antibodies
- Interferons Alpha and Beta
Breakup by Therapy Area:
- Autoimmune and Inflammatory Diseases
- Infectious Diseases
Breakup by End User:
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Key highlights of the report:
- Market Performance (2017-2022)
- Market Outlook (2023- 2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
|Base Year of the Analysis||2022|
|Segment Coverage||Type, Therapy Area, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GSK plc, Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499|
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their business.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Also Visit: https://37r.net/
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800